

Corporate Office
Torrent House,
Off Ashram Road,
Ahmedabad-380 009,
India,
Phone : (079) 26585090 /
26583060
Fax : (079) 26582100

July 26, 2013

The Dy. General Manager (Listing Dept.)
Bombay Stock Exchange Limited
Corporate Relationship Dept.,
1st Floor, New Trading Ring,
P. J. Towers, Dalal Street, Fort,
Mumbai - 400 001
(BSE Scrip Code: 500420)

The Manager – Listing Dept.,
National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G. Block,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051
(NSE Scrip Code: TORNTPHARM)

Dear Sir,

Sub.: Financial Results for the quarter ended on 30th June, 2013

We enclose herewith the following:

1. Audited Standalone Financial Results along with audit report thereon and Unaudited Consolidated Financial Results along with the limited review report of the Company for the quarter ended on 30th June, 2013 as per clause 41 of the Listing Agreement, which were approved by the Board of Directors at its meeting held on 26th July, 2013.

In terms of clause 41(VI) (b) of the Listing Agreement, the Company will publish above Unaudited Consolidated Financial Results for the quarter ended on 30th June, 2013. Both Standalone and Consolidated Financial Results will be available at Company's website www.torrentpharma.com.

2. Press Release on Financial Results as being submitted to the press media.

The above is for your information and record.

Thanking you.

Yours faithfully,

For TORRENT PHARMACEUTICALS LIMITED



MAHESH AGRAWAL
VP (LEGAL) & COMPANY SECRETARY

Encl.: A/a

**INDEPENDENT AUDITORS' REPORT
TO THE BOARD OF DIRECTORS OF
TORRENT PHARMACEUTICALS LIMITED**

1. We have audited the accompanying Statement of Standalone Financial Results of **TORRENT PHARMACEUTICALS LIMITED** ("the Company") for the Quarter Ended 30th June, 2013 ("the Statement"), being submitted by the Company pursuant to Clause 41 of the Listing Agreements with the Stock Exchanges, except for the disclosures in Part II - Select Information referred to in paragraph 4 below. This Statement has been prepared on the basis of the related interim financial statement, which is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to express an opinion on the Statement, based on our audit of the related interim financial statements, which has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS-25) on Interim Financial Reporting notified under the Companies (Accounting Standards) Rules, 2006 as per Section 211(3C) of the Companies Act, 1956 and other accounting principles generally accepted in India.
2. We conducted our audit of the Statement in accordance with the auditing standards generally accepted in India. Those Standards require that we plan and perform the audit to obtain reasonable assurance about whether the Statement is free of material misstatements. An audit includes examining, on a test basis, evidence supporting the amounts and the disclosures in the Statement. An audit also includes assessing the accounting principles used and the significant estimates made by the Management, as well as evaluating the overall Statement presentation. We believe that our audit provides a reasonable basis for our opinion.
3. In our opinion and to the best of our information and according to the explanations given to us, the Statement:
 - (i) is presented in accordance with the requirements of Clause 41 of the Listing Agreements with the Stock Exchanges and
 - (ii) gives a true and fair view in conformity with the accounting principles generally accepted in India of the net profit and other financial information of the Company for the Quarter Ended 30th June, 2013.

K

Deloitte Haskins & Sells

Deloitte Haskins & Sells
Chartered Accountants
Heritage, 3rd Floor
Near Gujarat Vidhyapeeth
Off Ashram Road
Ahmedabad - 380 014
Tel: +91 (079) 27582542
+91 (079) 27582543
+91 (079) 86079100
Fax: +91 (079) 27582551

4. Further, we also report that we have traced the number of shares as well as the percentage of shareholdings in respect of the aggregate amount of public shareholdings and the number of shares as well as the percentage of shares pledged/encumbered and non-encumbered in respect of the aggregate amount of promoters and promoter group shareholding, in terms of Clause 35 of the Listing Agreements and the particulars relating to the investor complaints disclosed in Part II - Select Information for the Quarter Ended 30th June, 2013 of the Statement, from the details furnished by the Management.

For DELOITTE HASKINS & SELLS
Chartered Accountants
(Firm Registration No. 117365W)




(Hemendra L. Shah)
Partner
(Membership No. 33590)

Place: Ahmedabad.
Date: 26th July, 2013



TORRENT PHARMACEUTICALS LIMITED

PART I		[Rs. in Crores except per share data]		
Statement of Standalone Audited Results for the Quarter Ended 30-Jun-2013				
Particulars	Quarter ended			Year ended
	30-Jun-2013	31-Mar-2013	30-Jun-2012	31-Mar-2013
Income from operations				
Net sales (Net of excise duty) (see note 2)	818	703	620	2618
Other operating income	67	67	29	149
Net income from operations	885	770	649	2767
Expenses				
Cost of materials consumed	212	224	176	797
Purchases of stock-in-trade	20	23	120	293
Changes in inventories of finished goods, work-in-progress and stock-in-trade	39	(24)	(49)	(110)
Employee benefits expense	104	98	88	366
Depreciation and amortisation expense	19	20	16	72
Other expenses	223	200	171	742
Total expenses	617	541	522	2160
Profit from operations before other income, finance costs and exceptional items	268	229	127	607
Other income	14	15	58	132
Profit from ordinary activities before finance costs and exceptional items	282	244	185	739
Finance costs	8	10	10	37
Profit from ordinary activities after finance costs but before exceptional items	274	234	175	702
Exceptional items	-	37	-	37
Profit from ordinary activities before tax	274	197	175	665
Tax expense	60	44	27	119
Net profit for the period	214	153	148	546
Paid-up equity share capital (Face value of Rs.5 each)	42	42	42	42
Reserves excluding revaluation reserves	-	-	-	1609
Earnings per share (of Rs. 5/- each) (not annualised):				
Basic	25.28	18.08	17.44	64.58
Diluted	25.28	18.08	17.44	64.58



2


PART II**Select Information for the Quarter Ended 30-Jun-2013**

PARTICULARS OF SHAREHOLDING	Quarter ended			Year ended
	30-Jun-2013	31-Mar-2013	30-Jun-2012	31-Mar-2013
Public shareholding				
- Number of shares	24108000	24108000	24109500	24108000
- Percentage of shareholding	28.49%	28.49%	28.49%	28.49%
Promoters and Promoter group Shareholding				
a) Pledged/Encumbered				
- Number of shares	Nil	Nil	Nil	Nil
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil
- Percentage of shares (as a % of the total share capital of the company)	Nil	Nil	Nil	Nil
b) Non-encumbered				
- Number of shares	60503360	60503360	60501860	60503360
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%
- Percentage of shares (as a % of the total share capital of the company)	71.51%	71.51%	71.51%	71.51%
INVESTOR COMPLAINTS	Quarter ended			
	30-Jun-2013			
Pending at the beginning of the quarter		Nil		
Received during the quarter		1		
Disposed of during the quarter		1		
Remaining unresolved at the end of the quarter		Nil		

Notes:


- The above results were reviewed by the Audit Committee and approved by the Board of Directors, in their respective meetings held on 26-Jul-2013. There is no qualification in the Auditors Report on this statement of financial results.
- The Company operates a solitary business segment viz. pharmaceuticals, comprising mainly manufacture of branded formulations. A further breakdown of pharmaceutical sales is given below.

Particulars	Quarter ended			Year ended
	30-Jun-2013	30-Jun-2012	Growth %	31-Mar-2013
(A) Sales in India				
Branded sales	316	280	13%	1035
Contract manufacture	60	48	25%	231
Others	3	3	-	12
Total sales in India	379	331	15%	1278
(B) Sales outside India	441	291	52%	1347
Total sales (A+B)	820	622	32%	2625
Less: Excise duty	2	2	-	7
Net sales	818	620	32%	2618



- 3 Other operating income during the current quarter, includes an amount of Rs. 42 crores (preceding quarter ended on 31-Mar-2013 Rs. 29 crores and comparative quarter ended on 30-Jun-2012 Rs. Nil) being the milestone payment arising from settlement and license agreement involving assignment of a patent.
- 4 The figures for the comparative periods have been regrouped, wherever necessary, to make them comparable with the figures for the current periods.
- 5 The Company has also prepared and published unaudited consolidated financial results for the quarter ended 30-Jun-2013, which were subjected to limited review by statutory auditors of the Company.

For TORRENT PHARMACEUTICALS LIMITED



SAMIR MEHTA

Executive Vice Chairman

Place : Ahmedabad, Gujarat

Date : 26-Jul-2013



.... Visit us at www.torrentpharma.com....



INDEPENDENT AUDITORS' REPORT TO THE BOARD OF DIRECTORS OF TORRENT PHARMACEUTICALS LIMITED

1. We have reviewed the accompanying statement of Consolidated Unaudited Financial Results of **TORRENT PHARMACEUTICALS LIMITED** ("the Company"), and its subsidiaries (the Company and its subsidiaries constitute "the Group") for the Quarter Ended 30th June, 2013 ("the Statement"), being submitted by the Company pursuant to Clause 41 of the Listing Agreements with the Stock Exchanges, except for the disclosures in Part II - Select Information referred to in paragraph 6 below. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial results based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatements. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. The Statement includes the results of the following subsidiaries:

(1) Zao Torrent Pharma, (2) Torrent Pharma GmbH, (3) Heumann Pharma GmbH & Co. Generica KG, (4) Torrent Do Brasil Ltda, (5) Torrent Pharma Philippines Inc., (6) Torrent Pharma Inc., (7) Laboratories Torrent S.A. de C.V., (8) Torrent Australasia Pty Ltd., (9) Heunet Pharma GmbH, (10) Norispharm GmbH, (11) Torrent Pharma Canada Inc., (12) Torrent Pharma (Thailand) Co., Limited. (13) Torrent Pharma S.R.L., (14) Torrent Pharma (UK) Limited, (15) Torrent Pharmaceuticals (Sikkim), (16) Laboratories Torrent (Malaysia) Sdn. Bhd and (17) Opening Pharma France S.A.S.
4. The consolidated financial results includes the interim financial results of sixteen subsidiaries which have not been reviewed by their auditors, whose interim financial results reflect total revenue of Rs. 410 Crores for the Quarter Ended 30th June 2013, and total (loss) after tax of Rs. (49) Crores for the Quarter Ended 30th June 2013, as considered in the consolidated financial results.

k

c

Deloitte Haskins & Sells

Deloitte Haskins & Sells
Chartered Accountants
Heritage, 3rd Floor,
Near Gujarat Vidhyapeeth,
Off Ashram Road,
Ahmedabad - 380 016
Tel: +91 (079) 27582542
+91 (079) 27582543
+91 (079) 66073100
Fax: +91 (079) 27582551

5. Based on our review conducted as stated above and except for the effects of the matter described in paragraph 4 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the Accounting Standards referred to in Section 211 (3C) of the Companies Act, 1956 and other recognised accounting practices and policies, has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreements with the stock exchanges, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. Further, we also report that we have traced the number of shares as well as the percentage of shareholdings in respect of the aggregate amount of public shareholding and the number of shares as well as the percentage of shares pledged/encumbered and non-encumbered in respect of the aggregate amount of promoters and promoter group shareholding in terms of Clause 35 of the Listing Agreements and the particulars relating to investor complaints disclosed in Part II - Select Information for the Quarter Ended 30th June, 2013 of the Statement, from the details furnished by the Management.

For DELOITTE HASKINS & SELLS
Chartered Accountants
(Firm Registration No. 117365W)



(Hemendra L. Shah)
Partner
Membership No. 33590

Place: Ahmedabad
Date: 26th July, 2013



TORRENT PHARMACEUTICALS LIMITED

PART I [Rs. in Crores except per share data]

Statement of Consolidated Results for the Quarter Ended on 30-Jun-2013

Particulars	Quarter ended (Unaudited)			Year ended (Audited)
	30-Jun-2013	31-Mar-2013	30-Jun-2012	31-Mar-2013
Income from operations				
Net sales (Net of excise duty) (see note 3)	903	803	736	3054
Other operating income (see note 4)	69	68	31	158
Net income from operations	972	871	767	3212
Expenses				
Cost of materials consumed	213	218	203	845
Purchases of stock-in-trade	117	82	64	295
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(26)	(57)	(47)	(214)
Employee benefits expense	172	164	152	623
Depreciation and amortisation expense	21	22	20	83
Other expenses	288	244	239	970
Total expenses	785	673	631	2602
Profit from operations before other income, finance costs and exceptional items	187	198	136	610
Other income	8	8	14	43
Profit from ordinary activities before finance costs and exceptional items	195	206	150	653
Finance costs	8	10	10	34
Profit from ordinary activities after finance costs but before exceptional items	187	196	140	619
Exceptional item	-	37	-	37
Profit from ordinary activities before tax	187	159	140	582
Tax expense	38	48	37	147
Net Profit for the period	149	111	103	435
Minority interest	0	0	1	2
Net Profit after taxes and minority interest	149	111	102	433
Paid-up equity share capital (Face value of Rs. 5 each)	42	42	42	42
Reserves excluding Revaluation Reserves	-	-	-	1380
Earnings per share (of Rs. 5/- each) (not annualised):				
Basic	17.61	13.12	12.04	51.15
Diluted	17.61	13.12	12.04	51.15



PART II				
Select Information for the Quarter Ended 30-Jun-2013				
PARTICULARS OF SHAREHOLDING	Quarter ended			Year ended
	30-Jun-2013	31-Mar-2013	30-Jun-2012	31-Mar-2013
Public shareholding				
- Number of shares	24108000	24108000	24109500	24108000
- Percentage of shareholding	28.49%	28.49%	28.49%	28.49%
Promoters and Promoter Group Shareholding				
(a) Pledged / Encumbered				
- Number of shares	Nil	Nil	Nil	Nil
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil
- Percentage of shares (as a % of the total share capital of the company)	Nil	Nil	Nil	Nil
(b) Non - encumbered				
- Number of shares	60503360	60503360	60501860	60503360
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%
- Percentage of shares (as a % of the total share capital of the company)	71.51%	71.51%	71.51%	71.51%
INVESTOR COMPLAINTS	Quarter ended			
	30-Jun-2013			
Pending at the beginning of the quarter	Nil			
Received during the quarter	1			
Disposed of during the quarter	1			
Remaining unresolved at the end of the quarter	Nil			

Notes:

- 1 The above results were reviewed by the Audit Committee and approved by the Board of Directors, in their respective meetings held on 26-Jul-2013.
- 2 The statement of financial results consolidate the financial results of sixteen wholly owned subsidiaries (including a subsidiary from 19-Jun-13) and one partnership firm with that of the Company.
- 3 The Company operates a solitary business segment viz. pharmaceuticals, comprising mainly manufacture of branded formulations. A further breakdown of pharmaceutical sales is given below.

Particulars	Quarter ended (Unaudited)			(Rs. in Crores)
	30-Jun-2013	30-Jun-2012	Growth %	Year ended (Audited) 31-Mar-2013
(A) Sales in India				
Branded sales	316	280	13%	1035
Contract manufacture	60	48	25%	231
Others	3	3	-	10
Total sales in India	379	331	15%	1276
(B) Sales outside India	526	407	29%	1785
Total sales (A+B)	905	738	23%	3061
Less: Excise duty	2	2	-	7
Net sales	903	736	23%	3054

- 4 Other operating income during the current quarter, includes an amount of Rs. 42 crores (preceding quarter ended on 31-Mar-2013 Rs. 29 crores and comparative quarter ended on 30-Jun-2012 Rs. Nil) being the milestone payment arising from settlement and license agreement involving assignment of a patent.




5 Summary details of stand-alone audited financial results of Torrent Pharmaceuticals Limited :

Particulars	Quarter ended			[Rs. in Crores]
	30-Jun-2013	31-Mar-2013	30-Jun-2012	Year ended 31-Mar-2013
Net income from operations	885	770	649	2767
Profit before tax	274	197	175	665
Profit after tax	214	153	148	546

- 6 The figures for the comparative periods have been regrouped, wherever necessary, to make them comparable with the figures for the current periods.
- 7 The stand-alone audited financial results for the quarter ended 30-Jun-2013 are available on the Company's website at www.torrentpharma.com.

For TORRENT PHARMACEUTICALS LIMITED



SAMIR MEHTA
Executive Vice Chairman

Place : Ahmedabad, Gujarat
Date : 26-Jul-2013



.... Visit us at www.torrentpharma.com....

PRESS RELEASE

Torrent Pharma records 44% growth in Net Profit and 27% in Revenues during Q1 13-14

Ahmedabad-based Pharmaceuticals major, Torrent Pharmaceuticals Limited, today released its financial results for the quarter ended 30th June, 2013. The Q1'13-14 revenues stood at ₹ 972 crores, up by 27% from ₹ 767 crores in the comparable quarter of last year.

During Q1, domestic formulation business recorded revenues of ₹ 312 crores, growing by 12%. International revenues grew by 28% to ₹ 539 crores. In the international operations, US business reported a growth of 43%, Europe 49%, Rest of the World, including Russia and CIS 23%, while Brazil registered a degrowth of 2%.

Profit before Taxes for the quarter was ₹ 187 crores compared to ₹ 140 crores during the same period last year. Profit after Taxes for the quarter was ₹ 149 crores compared to ₹ 102 crores during the same period last year.

About Torrent Pharma: Torrent Pharma, with an annual turnover of over ₹ 3200 crores is the flagship Company of the Torrent Group. With many of its products ranking among the top 200 brands, Torrent continues to be at the forefront of the Indian pharmaceutical industry through research, innovation and breakthroughs in the therapeutics areas of Diabetology, Cardiovascular, Central Nervous System, Gastro-Intestinal, Anti-infective, Pain management and Gynecology. Its Research Center employs over 580 scientists in the areas of drug discovery and development. Torrent's manufacturing plant at Chatral has a capacity to manufacture approx. 5,500 million tablets, capsules and vials and 45,000 kgs of Bulk Drugs/API. The facility has been approved by authorities from regulated markets like US, UK, Germany, Australia and South Africa. The manufacturing plant at Baddi has a capacity to manufacture 3,300 million tablets and 350 million capsules. Manufacturing plant at Sikkim has a capacity to manufacture 3,900 million tablets per annum.

